[1]李晓盈,张 鑫,张伟健,等.MLH1基因启动子甲基化在子宫内膜癌中的应用研究进展[J].陕西医学杂志,2025,54(5):711-715,720.[doi:DOI:10.3969/j.issn.1000-7377.2025.05.028]
　LI Xiaoying,ZHANG Xin,ZHANG Weijian,et al.Research progress on the application of MLH1 promoter methylation in endometrial cancer[J].,2025,54(5):711-715,720.[doi:DOI:10.3969/j.issn.1000-7377.2025.05.028]
点击复制

MLH1基因启动子甲基化在子宫内膜癌中的应用研究进展
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
54
期数:
2025年5期
页码:
711-715,720
栏目:
出版日期:
2025-05-05

文章信息/Info

Title:
Research progress on the application of MLH1 promoter methylation in endometrial cancer
作者:
李晓盈1; 张 鑫2; 张伟健2; 阮晓红2
(1.广东医科大学第一临床医学院,广东 湛江 524023; 2.广东医科大学江门市中心医院,广东 江门 529030)
Author(s):
LI Xiaoying1; ZHANG Xin2; ZHANG Weijian2; RUAN Xiaohong2
(1.The First Clinical Medical College,Guangdong Medical University,Zhanjiang 524023,China; 2.Jiangmen Central Hospital,Guangdong Medical University,Jiangmen 529030,China)
关键词:
子宫内膜癌;  MutL同源物1;  启动子甲基化;  错配修复缺陷;  表观遗传
Keywords:
Endometrial cancer;  MLH1;  Promoter methylation;  Mismatch repair deficiency;  Epigenetics
分类号:
R 737.33
DOI:
DOI:10.3969/j.issn.1000-7377.2025.05.028
文献标志码:
A
摘要:
子宫内膜癌(EC)是女性生殖系统常见的恶性肿瘤。近年来,表观遗传学机制在EC的发生和发展中引起了广泛关注。其中,MutL同源物1(MLH1)基因启动子区甲基化是EC常见的表观遗传改变,可导致基因沉默,进而引起微卫星不稳定性(MSI)。研究发现,MLH1基因启动子甲基化不仅参与EC的发生和发展,还可影响其诊断、治疗及预后。现对MLH1基因启动子甲基化的分子机制、检测方法及其在EC临床诊断、治疗策略及预后评估中的应用进行综述。
Abstract:
Endometrial cancer(EC)is a common malignant tumor of the female reproductive system.In recent years,epigenetic mechanisms have attracted widespread attention in the occurrence and development of EC.Among these mechanisms,methylation of the MutL homolog 1(MLH1)gene promoter is a frequent epigenetic alteration in EC,leading to gene silencing and subsequent microsatellite instability.Studies have shown that MLH1 promoter methylation is not only involved in the occurrence and development of EC but also affects its diagnosis,treatment and prognosis.This article reviews the molecular mechanisms,detection methods and applications of MLH1 promoter methylation in the clinical diagnosis,treatment strategies and prognostic evaluation of EC.

参考文献/References:

[1] SIEGEL R L,MILLER K D,FUCHS H E,et al.Cancer statistics,2022[J].CA Cancer J Clin,2022,72(1):7-33.
[2] 邓波儿,孔为民.子宫内膜癌的表观遗传学研究进展[J].国际肿瘤学杂志,2021,48(3):184-188.
[3] XU T,DING H,CHEN J,et al.Research progress of DNA methylation in endometrial cancer[J].Biomolecules,2022,12(7):938.
[4] 刘红,王登凤,刘洋,等.《Lynch综合征相关性子宫内膜癌筛查与防治中国专家共识(2023年版)》解读[J].肿瘤预防与治疗,2023,36(3):194-199.
[5] KADYROV F A,DZANTIEV L,CONSTANTIN N,et al.Endonucleolytic function of MutLalpha in human mismatch repair[J].Cell,2006,126(2):297-308.
[6] STELLOO E,JANSEN A M L,OSSE E M,et al.Practical guidance for mismatch repair-deficiency testing in endometrial cancer[J].Ann Oncol,2017,28(1):96-102.
[7] 中国抗癌协会肿瘤标志专业委员会.肿瘤DNA甲基化标志物检测及临床应用专家共识(2024版)[J].中国癌症防治杂志,2024,16(2):129-142.
[8] MEDVEDEVA Y A,FRIDMAN M V,OPARINA N J,et al.Intergenic,gene terminal,and intragenic CpG islands in the human genome[J].BMC Genomics,2010,11:48.
[9] 宫时玉,蒋曹德,邓昌彦.DNA甲基化及其生物学功能[J].华中农业大学学报(自然科学版),2005,24(6):651-657.
[10] 钟焱,徐慧,彭凤兰.DNA甲基化在基因表达调控中的意义及研究进展[J].中国医药导报,2019,16(14):33-36.
[11] 闫伟伟,黄昂,戴广海.MBD蛋白家族研究进展[J].传染病信息,2017,30(3):181-185.
[12] FIRNAU M B,PLOTZ G,ZEUZEM S,et al.Key role of phosphorylation sites in ATPase domain and Linker region of MLH1 for DNA binding and functionality of MutLα[J].Sci Rep,2023,13(1):12503.
[13] GELSOMINO F,BARBOLINI M,SPALLANZANI A,et al.The evolving role of microsatellite instability in colorectal cancer:A review[J].Cancer Treat Rev,2016,51:19-26.
[14] CORNEL K M C,WOUTERS K,VAN-DE-VIJVER K K,et al.Gene promoter methylation in endometrial carcinogenesis[J].Pathol Oncol Res,2019,25(2):659-667.
[15] LEE A V,NESTLER K A,CHIAPPINELLI K B.Therapeutic targeting of DNA methylation alterations in cancer[J].Pharmacol Ther,2024,258:108640.
[16] JUNYA T,MASATAKA T,AIKOU O,et al.Molecular typing guiding treatment and prognosis of endometrial cancer[J].Gynecol Obstet Clin Med,2023,3(1):7-17.
[17] 杨苏彬,许凤燕.PD-1/PD-L1及其与免疫相关疾病的研究进展[J].国际遗传学杂志,2020,43(4):224-228.
[18] TOBONI M D,WU S,FARRELL A,et al.Differential outcomes and immune checkpoint inhibitor response among endometrial cancer patients with MLH1 hypermethylation versus MLH1 “Lynch-like” mismatch repair gene mutation[J].Gynecol Oncol,2023,177:132-141.
[19] KREMER L P M,BRAUN M M,OVCHINNIKOVA S,et al.Analyzing single-cell bisulfite sequencing data with MethSCAn[J].Nat Methods,2024,21(9):1616-1623.
[20] SCHAFER E,IRIZARRY R,NEGI S,et al.Promoter hypermethylation in MLL-r infant acute lymphoblastic leukemia:Biology and therapeutic targeting[J].Blood,2010,115(23):4798-4809.
[21] 顾丰.焦磷酸光化测序技术的发展和应用[J].生命科学,2020,32(5):515-521.
[22] 关明.DNA甲基化定量检测的新方法:甲基化敏感性高分辨率熔解分析[J].中华检验医学杂志,2010,33(3):197-200.
[23] MAI L,WEN Z,ZHANG Y,et al.Shortcut barcoding and early pooling for scalable multiplex single-cell reduced-representation CpG methylation sequencing at single nucleotide resolution[J].Nucleic Acids Res,2023,51(21):108.
[24] TSUTSUI H,GROSSNIKLAUS U.Whole-genome bisulfite sequencing with a small amount of DNA[J].Methods Mol Biol,2025,2873:3-17.
[25] JEONG Y,GERH?SER C,SAUTER G,et al.MethylBERT enables read-level DNA methylation pattern identification and tumour deconvolution using a transformer-based model[J].Nat Commun,2025,16(1):788.
[26] 陈瑶,李阳,吕卫国.错配修复通路缺陷型子宫内膜癌的临床病理特点及其治疗的研究进展[J].中华医学杂志,2023,1039(20):1580-1584.
[27] 中国抗癌协会妇科肿瘤专业委员会,中华医学会病理学分会,国家病理质控中心.子宫内膜癌分子检测中国专家共识(2021年版)[J].中国癌症杂志,2021,31(11):1126-1144.
[28] 刘岩,王玉湘,孙小婕,等.子宫内膜癌分子分型中错配修复和微卫星不稳定性状态的综合评估[J].中华妇产科杂志,2023,58(10):755-765.
[29] ZHAO S,CHEN L,ZANG Y,et al.Endometrial cancer in Lynch syndrome[J].Int J Cancer,2022,150(1):7-17.
[30] FERGUSON S E,ARONSON M,POLLETT A,et al.Performance characteristics of screening strategies for Lynch syndrome in unselected women with newly diagnosed endometrial cancer who have undergone universal germline mutation testing[J].Cancer,2014,120(24):3932-3939.
[31] CROSBIE E J,RYAN N A J,ARENDS M J,et al.The manchester international consensus group recommendations for the management of gynecological cancers in Lynch syndrome[J].Genet Med,2019,21(10):2390-2400.
[32] YOKOYAMA T,TAKEHARA K,SUGIMOTO N,et al.Lynch syndrome-associated endometrial carcinoma with MLH1 germline mutation and MLH1 promoter hypermethylation:A case report and literature review[J].BMC Cancer,2018,18(1):576.
[33] HELDERMAN N C,ANDINI K D,VAN-LEERDAM M E,et al.MLH1 promotor hypermethylation in colorectal and endometrial carcinomas from patients with Lynch syndrome[J].J Mol Diagn,2024,26(2):106-114.
[34] CARNEVALI I W,CINI G,LIBERA L,et al.MLH1 promoter methylation could be the second hit in Lynch syndrome carcinogenesis[J].Genes(Basel),2023,14(11):2060.
[35] ZYLA R,GRAHAM T,ARONSON M,et al.MLH1 epimutation is a rare mechanism for Lynch syndrome:A case report and review of the literature[J].Genes Chromosomes Cancer,2021,60(9):635-639.
[36] DáMASO E,CASTILLEJO A,ARIAS M D M,et al.Primary constitutional MLH1 epimutations:A focal epigenetic event[J].Br J Cancer,2018,119(8):978-987.
[37] HITCHINS M P.The role of epigenetics in Lynch syndrome[J].Fam Cancer,2013,12(2):189-205.
[38] HITCHINS M P,ALVAREZ R,ZHOU L,et al.MLH1-methylated endometrial cancer under 60 years of age as the “sentinel” cancer in female carriers of high-risk constitutional MLH1 epimutation[J].Gynecol Oncol,2023,171:129-140.
[39] HITCHINS M P,DáMASO E,ALVAREZ R,et al.Constitutional MLH1 methylation is a major contributor to mismatch repair-deficient,MLH1-methylated colorectal cancer in patients aged 55 years and younger[J].J Natl Compr Canc Netw,2023,21(7):743-752.
[40] 中国临床肿瘤学会指南工作委员会.中国临床肿瘤学会(CSCO)子宫内膜癌诊疗指南2024[M].北京:人民卫生出版社,2024:43-44.
[41] 中国研究型医院学会妇产科学专业委员会,王建六,王志启.子宫内膜癌分子分型临床应用中国专家共识(2024年版)[J].中国实用妇科与产科杂志,2024,40(6):638-644.
[42] REIJNEN C,KüSTERS-VANDEVELDE H V N,PRINSEN C F,et al.Mismatch repair deficiency as a predictive marker for response to adjuvant radiotherapy in endometrial cancer[J].Gynecol Oncol,2019,154(1):124-130.
[43] SHERWANI Z,DAMAST S,HAN J,et al.The prognostic impact of MLH1 promoter hypermethylation in stage Ⅰ-Ⅱ endometrial cancer treated with adjuvant radiotherapy[J].Int J Radiat Oncol Biol Phys,2024,109(1):123-132.
[44] LE D T,DURHAM J N,SMITH K N,et al.Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade[J].Science,2017,357(6349):409-413.
[45] MANDAL R,SAMSTEIN R M,LEE K W,et al.Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response[J].Science,2019,364(6439):485-491.
[46] ESKANDER R N,SILL M W,BEFFA L,et al.Pembrolizumab plus chemotherapy in advanced endometrial cancer[J].N Engl J Med,2023,388(23):2159-2170.
[47] O’MALLEY D M,BARIANI G M,CASSIER P A,et al.Pembrolizumab in microsatellite instability-high/mismatch repair deficient(MSI-H/dMMR)and non-MSI-H/non-dMMR advanced endometrial cancer:Phase 2 KEYNOTE-158 study results[J].Gynecol Oncol,2025,193:130-135.
[48] CHOW R D,MICHAELS T,BELLONE S,et al.Distinct mechanisms of mismatch-repair deficiency delineate two modes of response to anti-PD-1 immunotherapy in endometrial carcinoma[J].Cancer Discov,2023,13(2):312-331.
[49] 邓玥,黄洵.表观遗传抗肿瘤药物的研发进展[J].中国肿瘤临床,2023,50(6):278-285.
[50] CHEN L,YIN N,DING Y,et al.Effects of fluoride on the proliferation and activation of osteoblasts by regulating methylation of the DNA repair genes MGMT and MLH1[J].Regen Ther,2022,19:107-112.

[51] FAN W,LI W,LI L,et al.Bifunctional HDAC and DNMT inhibitor induces viral mimicry activates the innate immune response in triple-negative breast cancer[J].Eur J Pharm Sci,2024,197:106767.
[52] HUANG W,ZHU Q,SHI Z,et al.Dual inhibitors of DNMT and HDAC induce viral mimicry to induce antitumour immunity in breast cancer[J].Cell Death Discov,2024,10(1):143.
[53] 林松荣,张磊,罗金现,等.DNA甲基化修饰在甲状腺癌中的研究进展[J].陕西医学杂志,2021,50(2):254-257.
[54] KANEKO E,SATO N,SUGAWARA T,et al.MLH1 promoter hypermethylation predicts poorer prognosis in mismatch repair deficiency endometrial carcinomas[J].J Gynecol Oncol,2021,32(6):79.
[55] SHIKAMA A,MINAGUCHI T,MATSUMOTO K,et al.Clinicopathologic implications of DNA mismatch repair status in endometrial carcinomas[J].Gynecol Oncol,2016,140(2):226-233.
[56] BELLONE S,ROQUE D M,SIEGEL E R,et al.A phase 2 evaluation of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability[J].Cancer,2022,128(6):1206-1218.
[57] SILVA F F V E,BALLINI A,CAPONIO V C A,et al.Insights into MLH1 methylation in endometrial adenocarcinoma through pyrosequencing analysis:A retrospective observational study[J].Cancers(Basel),2024,16(11):2119.

相似文献/References:

[1]冯苗苗,曹秋雨.miR335在子宫内膜癌患者血清中的表达及检测临床意义[J].陕西医学杂志,2019,(2):252.
　FENG Miaomiao,CAO Qiuyu..The expression and significance of miR335 in serum of patients with endometrial carcinoma[J].,2019,(5):252.
[2]刘家利,谢小军.子宫内膜癌组织HIF-1α、血清CA125水平在患者病情与疾病预后评估中的价值[J].陕西医学杂志,2019,(6):800.
[3]张晓勇.宫腔镜辅助下分段诊刮术与单纯分段诊刮术诊断子宫内膜癌价值比较[J].陕西医学杂志,2019,(8):1045.
　ZHANG Xiaoyong..Comparison of hysteroscopy assisted dilatation and curettage and traditional dilatation  and curettage in the diagnosis of endometrial carcinoma[J].,2019,(5):1045.
[4]徐 珊,程 珂,刘鹏宇.子宫内膜癌组织血管紧张素(1-7)、miR-106b表达与患者临床病理分期相关性研究[J].陕西医学杂志,2022,51(5):621.[doi:DOI:10.3969/j.issn.1000-7377.2022.05.025]
　XU Shan,Cheng Ke,LIU Pengyu.Correlation between the expression of angiotensin(1-7),miR-106b in endometrial cancer tissue and clinicopathological stage of patients[J].,2022,51(5):621.[doi:DOI:10.3969/j.issn.1000-7377.2022.05.025]
[5]都 燕,代 佳.血清细胞角蛋白19片段、α-烯醇化酶检测在子宫内膜癌诊断及病情严重程度评估中的价值[J].陕西医学杂志,2023,52(2):212.[doi:DOI:10.3969/j.issn.1000-7377.2023.02.022]
　DU Yan,DAI Jia.Value of serum cytokeratin 19 fragment and α-enolase detection in diagnosis and severity assessment of endometrial carcinoma[J].,2023,52(5):212.[doi:DOI:10.3969/j.issn.1000-7377.2023.02.022]
[6]姚 田,马文娟.RP11-444D3.1与SOX5基因共表达激活cofilin/LIMK/Rac信号通路介导子宫内膜癌侵袭机制研究[J].陕西医学杂志,2023,52(4):390.[doi:DOI:10.3969/j.issn.1000-7377.2023.04.006]
　YAO Tian,MA Wenjuan.Co-expression of RP11-444D3.1 and SOX5 enhances endometrial cancer invasion by activating cofilin/LIMK/Rac pathway[J].,2023,52(5):390.[doi:DOI:10.3969/j.issn.1000-7377.2023.04.006]
[7]查善辉,刘 杰,任 洁,等.腹腔镜手术治疗老年子宫内膜癌疗效及对患者应激、疼痛和术后恢复的影响[J].陕西医学杂志,2023,52(5):536.[doi:DOI:10.3969/j.issn.1000-7377.2023.05.009]
　ZHA Shanhui,LIU Jie,REN Jie,et al.Clinical effect of laparoscopic surgery in treatment of elderly endometrial cancer and its influence on patients' stress,pain and postoperative recovery[J].,2023,52(5):536.[doi:DOI:10.3969/j.issn.1000-7377.2023.05.009]
[8]冯一平,袁浩鑫,曾尚云,等.肿瘤坏死因子受体相关因子6高表达对子宫内膜癌细胞侵袭、迁移及上皮间质转化的影响[J].陕西医学杂志,2023,52(11):1598.[doi:DOI:10.3969/j.issn.1000-7377.2023.11.032]
　FENG Yiping,YUAN Haoxin,ZENG Shangyun,et al.Effects of high expression of TRAF6 on invasion,migration and epithelial-mesenchymal transition of endometrial cancer cells[J].,2023,52(5):1598.[doi:DOI:10.3969/j.issn.1000-7377.2023.11.032]
[9]孔维娜,李 佳,赵淑华,等.代谢综合征在子宫内膜癌及其肿瘤微环境中的研究进展[J].陕西医学杂志,2023,52(11):1607.[doi:DOI:10.3969/j.issn.1000-7377.2023.11.034]
　KONG Weina,LI Jia,ZHAO Shuhua,et al.Progress of metabolic syndrome in endometrial cancer and its tumor microenvironment[J].,2023,52(5):1607.[doi:DOI:10.3969/j.issn.1000-7377.2023.11.034]
[10]左学骞,赵海波,李 丹.三结构域蛋白8、Ras相关蛋白35、多聚ADP核糖聚合酶1在子宫内膜癌组织中的表达及检测临床意义[J].陕西医学杂志,2024,(2):266.[doi:DOI:10.3969/j.issn.1000-7377.2024.02.026]

备注/Memo

备注/Memo:
[基金项目]国家自然科学基金资助项目(81802918); 广东省科技创新战略资金资助项目(2019A1515011565); 广东省江门市科技计划项目(2020030103110009027)
更新日期/Last Update: 2025-05-05